Abstract
This review summarizes the available evidence on the cardioprotective effects of trimetazidine, focus-ing on clinical studies in a large spectrum of patients, including those with stable angina pectoris, acute myocardial infarction, ischemic cardiomyopathy, heart failure, and those undergoing percutane-ous coronary intervention. The cardioprotective effects of trimetazidine have been proven both in experimental and in clinical studies.
However, the evidence for a more robust clinical benefit (hard end points) is still awaited.